B+
Bull case
25%
Probability
Target price
$32.00
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
KMTS
Kestra MedicalFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$17.00
Analysis reference price unavailable
Analysis 2026-09-17 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-17
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+41.1
Score
AI commentary
The company release supports positive revenue, margin and guidance conclusions, while the earnings miss and widening losses make the post-print interpretation mixed. Secondary market data show a volatile reaction: shares fell about 9.6% after hours following the September 14 release, then closed September 15 at $25.18, up about 4.7% from the September 14 close, before retreating to the $24.08 September 16 anchor. That anchor was essentially unchanged from the $24.06 pre-release close but about 5.4% above the September 11 close, so the initial reaction neither held cleanly nor became a sustained selloff. September 15 rating trackers showed supportive reiterations and $30-$32 targets, but detailed estimate revisions remain unavailable. Social, options, short-interest and employee-sentiment evidence was not supplied; zero values denote missing data rather than neutral readings. The deterministic prior remains negative across 20-120 days, supporting a cautious monitoring stance.
RankAlpha Sentiment Codex - 2026-09-17
Open post-earnings memoEvidence flagged
later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
Impact
tentative
Confidence
-
AI events
2026-09-14eventRevenue beat and guidance raise offset by earnings missMedium impact
The SEC-filed company release reported fiscal Q1 revenue of $31.0 million, approximately 7% above the stored $29.01 million pre-earnings consensus, and raised FY2027 revenue guidance from $137 million to $141 million. Secondary post-print coverage reported an adjusted loss of $0.75 per share versus roughly $0.63 expected, explaining why the otherwise positive revenue update produced a mixed reaction. [#SEC-8K-2026-09-14] [#PR-EARNINGS-2026-09-11]
2026-12-31catalystLoss growth and investment intensity challenge the post-earnings reratingHigh impact
GAAP net loss widened to $44.1 million from $25.8 million and adjusted EBITDA loss widened to $24.0 million from $19.4 million as commercial and R&D investment increased. Failure to pair growth with improving operating leverage could reverse enthusiasm around the guidance raise. [#SEC-8K-2026-09-14]
2027-04-30catalystCommercial expansion and WCD share gains sustain elevated growthHigh impact
Management attributed 60% year-over-year revenue growth to wearable cardioverter defibrillator market expansion, competitive share gains, new territories, a higher in-network mix and improved revenue-cycle execution. Delivering the new $141 million FY2027 target would validate that these drivers remain durable. [#SEC-8K-2026-09-14]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-17 • Updated nightlySource: Internal modelMethodology